Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
about
Desensitization for solid organ and hematopoietic stem cell transplantationIs genetic rescue of cystinosis an achievable treatment goal?Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation.Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemiaHematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis.Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate.How do I perform hematopoietic progenitor cell selection?Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.Emerging drugs for graft-versus-host disease.Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function.Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.
P2860
Q26863564-02C90D0A-CF83-4F9C-86E4-8565D904481FQ27023975-CBA5E1C9-6FA1-4636-9933-8E44A6AA35D4Q33685495-832AF36A-6102-46FB-953C-96A3FD566D56Q34640239-0C4E15A0-FA81-4508-950D-8EFC9D54F57DQ34990554-05966C76-F426-4C10-8AB0-D11DDA93B872Q35083281-92143251-142E-491E-94EF-F947CE16CA64Q36057916-0FBA060C-11DC-4464-B3D3-9ABD5F795800Q36673678-9365083A-1AE8-4D18-8994-8B0C3E1372FBQ37973855-A2984C9A-120F-4312-B5DC-BE8F1B4C06F9Q38751575-CC5E9AA9-CF85-4E10-AFB1-3C8BD849BB55Q38753771-0B57AC11-A85B-4AE4-974B-BD011FE241CBQ38786084-37112DDF-FF38-426B-B749-98FB9101A5C3Q39037369-90427DAB-F0BF-4A8F-85DD-DE80BA93CF6FQ39595063-C1D6777A-3827-44E3-B918-84CE696E5117Q41031184-79CB73A4-F0ED-44A2-991D-469534FC2998Q48622749-11CC2593-AA8B-461C-B52D-B5B2DFE46322
P2860
Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute graft-versus-host diseas ...... es and conditioning intensity.
@en
Acute graft-versus-host diseas ...... es and conditioning intensity.
@nl
type
label
Acute graft-versus-host diseas ...... es and conditioning intensity.
@en
Acute graft-versus-host diseas ...... es and conditioning intensity.
@nl
prefLabel
Acute graft-versus-host diseas ...... es and conditioning intensity.
@en
Acute graft-versus-host diseas ...... es and conditioning intensity.
@nl
P1476
Acute graft-versus-host diseas ...... es and conditioning intensity.
@en
P2093
Laura Johnston
P304
P356
10.1016/J.BEHA.2008.02.006
P577
2008-06-01T00:00:00Z